drugset / Trial / NCT00384111
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP. The two patient groups will be compared to determine if Zevalin given after R-CVP therapy provides greater benefits than receiving no additional anti-cancer therapy after R-CVP.
Timeline
- Start
- 2006-10
- Primary completion
- 2008-11
- Completion
- 2008-11
Outcome
Outcome not reported
Stopped: “Study was terminated early as per the Sponsor's decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | — |
| Background | Vincristine | Small molecule | — | — |